Lech Ignatowicz, PhD

Lech Ignatowicz has extensive work experience in the biotechnology and research fields. Lech is currently serving as the Chief Executive Officer and Co-Founder of Molecular Attraction AB since October 2021. Prior to this, they held the role of Chief Executive Officer and Board member at Biopromic, a company focused on developing rapid, point-of-care diagnostics for infectious diseases.

Lech has also been actively involved in the investment and leadership roles at Moligo Technologies, where they serve as the Chairman of the Board and Founding Investor starting from 2019. In addition, they have worked as a Senior Scientific Officer at in2cure and as a Research Fellow at Lund University.

Lech started their career as a PhD Student at Karolinska Institutet and completed their doctoral studies in October 2012.

Throughout their career, Lech has demonstrated their expertise in biotechnology, business development, and leadership, making significant contributions to the advancement of diagnostic technologies in healthcare.

Lech Ignatowicz's education history begins in 2001 at the University of Warsaw, where they pursued a Bachelor of Science degree in Biotechnology, which they completed in 2004. Following this, from 2004 to 2006, Lech pursued a Master of Science degree in Microbiology, still at the University of Warsaw. In 2005, they also spent a year at Vrije Universiteit Brussel, where they continued their studies in Microbiology. Lech then went on to pursue a Doctor of Philosophy (PhD) degree in Immunology at Karolinska Institutet from 2006 to 2012.